arrow
N

Naoki Hosen

the university of osaka
H指数:41
被引数:6,152

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lifelong phylogenetic reconstruction of immune-mediated clonal trajectories in paroxysmal nocturnal hemoglobinuria

在阵发性睡眠性血红蛋白尿症中免疫介导的克隆轨迹的终身系统发育重建

Leukemia
IF13.4
2026-07-130
PRE
A small proportion of CD8 T cells expand robustly when stimulated with BCMAxCD3 bispecific T-cell engagers in vitro

在体外用BCMAxCD3双特异性T细胞结合剂刺激时,一小部分CD8 T细胞表现出显著的增殖反应

Leukemia
IF13.4
2026-04-270
PRE
Distinct fibrosis-associated macrophage subsets coordinate iron metabolism in pulmonary fibrosis

特异的纤维化相关巨噬细胞亚群协同调控肺纤维化中的铁代谢

2026-04-010
PRE
Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum

从关西骨髓瘤论坛对极高龄多发性骨髓瘤治疗的见解

2025-12-310
PRE
Successful treatment of refractory DLBCL coexisting with SLE using Liso-cel, complicated by cytokine release syndrome

使用Liso-cel成功治疗难治性DLBCL合并SLE,但伴有细胞因子释放综合征

2025-12-010
PRE
Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation

肠球菌在异基因造血干细胞移植后,通过磷酸转移酶系统在紊乱的肠道微生物群中增殖。

2025-09-070
OAAI
Treatment burden in patients with paroxysmal nocturnal hemoglobinuria: an in-depth interview survey

阵发性夜间血红蛋白尿症患者治疗负担:一项深度访谈调查

2025-07-180
OAAI
Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma

前列腺素F2受体负向调节剂作为胶质母细胞瘤嵌合抗原受体-T细胞疗法的潜在靶点

2025-03-060
OA
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
2024-08-210
PRE
CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy
2024-08-020
OAAI
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

daratumumab后elotuzumab治疗多发性骨髓瘤的疗效恶化: 一项多中心回顾性研究

2024-03-161
PRE
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8+T cell cytotoxicity and proliferation
2023-05-1910
OAAI
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
2023-03-295
OAAI
XCR1+conventional dendritic cell-induced CD4+T helper 1 cell activation exacerbates cardiac remodeling after ischemic myocardial injury
2023-03-015
OAAI